The delta variant is the fastest, fittest and most formidable version of the coronavirus that causes COVID-19 the world has encountered.
For Julie Steenhuysen's latest contributions to The Japan Times, see below:
Researchers are trying to determine just what level of antibodies a vaccine must produce to provide protection against the illness.
The drugmaker's push for health regulators to authorize a third dose of its COVID-19 shot is not yet backed by evidence, despite the fast-spreading delta variant, vaccine experts said.
The drug was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the disease.
Emergence of the same few mutations simultaneously in different parts of the world gives scientists cautious optimism that there may be limits on the pandemic's endurance.
Vaccine breakthroughs had initially sparked hope that the virus could be largely contained, but data on new variants has undercut that optimism.
The efforts rely on grassroots partners such as churches and health centers, and aim to topple long-standing barriers that keep minorities from participating in trials.
After developing and rolling out COVID-19 vaccines at record speed, drugmakers are already facing variants of the rapidly-evolving coronavirus that may render them ineffective.
Researchers were asked to tackle something that had never been done before: design a vaccine to stop a pandemic in its tracks in less than a year.
High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say. CanSino Biologics' vaccine, approved for military use in China, is a ...